Tenecteplase Shows Promise in Treating Acute Central Retinal Artery Occlusion

A new randomized trial published February 26, 2026, in The New England Journal of Medicine explores the use of tenecteplase, a thrombolytic drug, in treating acute central retinal artery occlusion (CRAO). CRAO, often described as a “stroke of the eye,” can lead to sudden and severe vision loss.

Understanding Central Retinal Artery Occlusion

The retina, the light-sensitive tissue at the back of the eye, relies on a constant supply of oxygen and nutrients delivered by the central retinal artery. When this artery becomes blocked – typically by a blood clot – the retina is deprived of blood, leading to rapid damage. Without prompt treatment, vision loss from CRAO is often permanent. Irreversible retinal damage can occur within hours of the blockage, underscoring the urgency of the situation.

The Trial Design and Findings

The study investigated whether administering tenecteplase, a medication commonly used to dissolve blood clots in stroke patients, could improve outcomes in individuals experiencing acute CRAO. Tenecteplase is a tissue plasminogen activator (tPA), working by converting plasminogen to plasmin, an enzyme that breaks down blood clots.

The trial was designed as a randomized controlled study, considered the gold standard for evaluating medical interventions. Specific details regarding the number of participants, the control group intervention, and the primary and secondary endpoints of the study are available in the full publication in The New England Journal of Medicine.

The publication details the methodology used to assess visual outcomes and safety parameters.

Further Information

The full details of this research, along with other peer-reviewed medical studies, can be found in the February 26, 2026 issue of The New England Journal of Medicine, Volume 394, Issue 9. Read more here.